Real-World Survival Outcomes of Patients with Malignant Pleural Mesothelioma by Physician's Choice of First-line Platinum Chemotherapy

被引：0
|
作者：
Kerrigan, K. [1 ]
Chipman, J. [2 ]
Jo, Y. J. [2 ]
Haaland, B. [3 ]
Johnson, E. [1 ]
Puri, S. [1 ]
Varghese, T. [1 ]
Akerley, W. [1 ]
Patel, S. [1 ]
机构：
[1] Huntsman Canc Inst, Med Oncol, Salt Lake City, UT USA
[2] Huntsman Canc Inst, Populat Hlth Sci, Salt Lake City, AL USA
[3] Huntsman Canc Inst, Populat Hlth Sci, Salt Lake City, UT USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
Real-world evidence; First-line platinum chemotherapy; Malignant Pleural Mesothelioma;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA09.05
引用
收藏
页码：S122 / S123
页数：2
相关论文
共 50 条
  • [41] Impact of Evolving Treatment Paradigms on Survival Outcomes in Advanced Pleural Mesothelioma: A Real-World Analysis
    Wu, F. T. H.
    Bhang, E.
    Sarvestani, M. Kamali
    Lee, C. W.
    Ho, C.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S383 - S383
  • [42] First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743
    Peters, S.
    Scherpereel, A.
    Cornelissen, R.
    Oulkhouir, Y.
    Greillier, L.
    Kaplan, M. A.
    Talbot, T.
    Monnet, I
    Hiret, S.
    Baas, P.
    Nowak, A. K.
    Fujimoto, N.
    Tsao, A. S.
    Mansfield, A. S.
    Popat, S.
    Zhang, X.
    Hu, N.
    Balli, D.
    Spires, T.
    Zalcman, G.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (05) : 488 - 499
  • [43] The effect of front-line chemotherapy on overall survival in patients with malignant pleural mesothelioma.
    Elkiran, Emin Tamer
    Sevinc, Alper
    Harputluoglu, Hakan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [44] THE EFFECT OF FRONT-LINE CHEMOTHERAPY ON OVERALL SURVIVAL IN PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA.
    Sevinc, Alper
    Elkiran, Emin T.
    Harputluoglu, Hakan
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S639 - S639
  • [45] Budget impact analysis of ttfields plus platinum-based therapy for first-line malignant pleural mesothelioma
    Wang, Bruce C.
    Furnback, Wesley
    Proescholdt, Christina
    Chavez, Gordon
    [J]. CANCER RESEARCH, 2020, 80 (16)
  • [46] REAL-WORLD TREATMENT PATTERNS AND CLINICAL OUTCOMES IN PATIENTS WITH METASTATIC NSCLC AFTER RECEIVING FIRST-LINE PEMBROLIZUMAB WITH PEMETREXED/PLATINUM CHEMOTHERAPY IN THE US ONCOLOGY NETWORK
    Goldschmidt, Jerome
    Annavarapu, Srinivas
    Venkatasetty, Divea
    Santorelli, Melissa
    Burke, Thomas
    Pennell, Nathan
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A974 - A975
  • [47] Real-World Survival Outcomes of Patients with Limited Stage Small Cell Lung Cancer (LS-SCLC) by Choice of Platinum Chemotherapy
    Kerrigan, K.
    Sinnott, J.
    Haaland, B.
    Puri, S.
    Akerley, W.
    Patel, S.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1186 - S1187
  • [48] Pemetrexed second-line treatment in malignant pleural mesothelioma (MPM) following platinum-based first-line treatment
    Sorensen, Jens B.
    Sundstrom, Stein
    Perell, Katharina
    Thielsen, Anne-Kathrine
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 216 - 216
  • [49] Real-World Outcomes Following Dose Modifications of First-Line Ibrutinib in Patients with Waldenstrom Macroglobulinemia
    Sarosiek, Shayna R.
    von Keudell, Gottfried R.
    Paludo, Jonas
    Salkar, Monika
    Agatep, Barnabie
    Franco, Anjali
    Crawford, Samuel
    Pacia, Michelle
    Castillo, Jorge J.
    [J]. BLOOD, 2023, 142
  • [50] First-Line Pembrolizumab Plus Chemotherapy for Advanced Squamous NSCLC: Real-World Outcomes at U.S. Oncology Practices
    Liu, Stephen V.
    Rai, Pragya
    Wang, Dong
    Hu, Xiaohan
    Schwarzenberger, Paul Otto
    [J]. JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (02):
12345